GlaxoSmithKline delivered Q2 sales of £6.5bn (3% above expectations) and core EPS of 24.5p (17% above expectations), up 4% on the comparable quarter last year at CER. There was a good performance across the board although the numbers were flattered by currency effects, positive supply issues and phasing of vaccine tenders.
The £192m sales beat was mainly driven by better-than-expected sales of Advair (boosted by a positive rebate adjustment in the...








